Download PDF
CC BY-NC-ND 4.0 · Ibnosina Journal of Medicine and Biomedical Sciences 2023; 15(01): 042-048
DOI: 10.1055/s-0043-1763492
Case Report

Juvenile Dermatomyositis and Diffuse Cutaneous Systemic Sclerosis Overlap

Hani Shatnawi
1   Division of Rheumatology, Department of Internal Medicine, Princess Basma Hospital, Irbid, Jordan
,
Dona Ailabouni
2   Department of Medicine, College of Medicine and Health sciences, United Arab Emirates University, Al Ain, Abu Dhabi, United Arab Emirates
,
Ahmad Mohammad Shatnawi
1   Division of Rheumatology, Department of Internal Medicine, Princess Basma Hospital, Irbid, Jordan
,
Faisal Mohammad Hussain Makahleh
3   Department of Internal Medicine, Princess Basma Hospital, Irbid, Jordan
,
Bader AlBalawi
4   Department of Pharmacy, Al Qurayyat Hospital, Saudi Arabia
,
Rajaie Namas 
5   Division of Rheumatology, Department of Internal Medicine, Cleveland Clinic Abu Dhabi, United Arab Emirates
› Author Affiliations Funding and Sponsorship None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

The overlapping nature of autoimmune diseases makes diagnosing and stratifying prognosis extremely difficult. Scleromyositis, the most common overlap syndrome, is typically seen in adults and is rarely seen in children. An overlap syndrome like scleromyositis would have clinical features of at least two connective tissue diseases (juvenile dermatomyositis and systemic sclerosis). Furthermore, the presence of anti-PM/Scl antibodies is critical. We describe a patient who presented with widespread skin tightening, hoarseness of voice, dysphagia, and muscle weakness that had been present for 6 months. The patient was diagnosed with overlap juvenile scleromyositis (scleroderma-dermatomyositis overlap). In practice, distinguishing this syndrome from dermatomyositis and scleroderma is critical.

Keywords

juvenile dermatomyositis - diffuse systemic sclerosis - scleroderma - Raynaud's phenomenon - connective tissue disease - overlap syndrome - scleromyositis - interstitial lung disease

Author Contributions

All authors contributed to the clinical care, data collection, manuscript drafting and revision. They all approved its final version.


Compliance with Ethical Principles

Written informed consent was obtained from the patient and parents for publication of the submitted article.




Publication History

Article published online:
17 March 2023

© 2023. The Libyan Biotechnology Research Center. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Jablonska S, Chorzelski TP, Blaszczyk M, Jarzabek-Chorzelska M, Kumar V, Beutner EH. Scleroderma/polymyositis overlap syndromes and their immunologic markers. Clin Dermatol 1992; 10 (04) 457-472
    CrossrefPubMedGoogle Scholar
  • 2 Christiphor-Stine L, Amato AA, Vleugels RA, Targoff IN, Shefner JM, Callen J, Curtis MR. Diagnosis and differential diagnosis of dermatomyositis and polymyositis in adults. UpToDate. https://www.uptodate.com/contents/diagnosis-and-differential-diagnosis-of-dermatomyositis-and-polymyositis-in-adults# . Published February 24, 2022. Accessed August 9, 2022
    Google Scholar
  • 3 Oldroyd A, Chinoy H. Recent developments in classification criteria and diagnosis guidelines for idiopathic inflammatory myopathies. Curr Opin Rheumatol 2018; 30 (06) 606-613
    CrossrefPubMedGoogle Scholar
  • 4 D'Aoust J, Hudson M, Tatibouet S. et al; Canadian Scleroderma Research Group. Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients. Arthritis Rheumatol 2014; 66 (06) 1608-1615
    CrossrefPubMedGoogle Scholar
  • 5 Wedderburn LR, McHugh NJ, Chinoy H. et al; Juvenile Dermatomyositis Research Group (JDRG). HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford) 2007; 46 (12) 1786-1791
    CrossrefPubMedGoogle Scholar
  • 6 Ranque B, Bérezné A, Le-Guern V. et al. Myopathies related to systemic sclerosis: a case-control study of associated clinical and immunological features. Scand J Rheumatol 2010; 39 (06) 498-505
    CrossrefPubMedGoogle Scholar
  • 7 Fairley JL, Hansen D, Proudman S. et al; Australian Scleroderma Interest Group. Clinical features of systemic sclerosis-mixed connective tissue disease and systemic sclerosis overlap syndromes. Arthritis Care Res (Hoboken) 2021; 73 (05) 732-741
    CrossrefPubMedGoogle Scholar
  • 8 Bhansing KJ, Lammens M, Knaapen HK, van Riel PL, van Engelen BG, Vonk MC. Scleroderma-polymyositis overlap syndrome versus idiopathic polymyositis and systemic sclerosis: a descriptive study on clinical features and myopathology. Arthritis Res Ther 2014; 16 (03) R111
    CrossrefPubMedGoogle Scholar
  • 9 Iaccarino L, Gatto M, Bettio S. et al. Overlap connective tissue disease syndromes. Autoimmun Rev 2013; 12 (03) 363-373
    CrossrefPubMedGoogle Scholar
  • 10 Fotis L, Baszis KW, White AJ, French AR. Four cases of anti-PM/SCL antibody-positive juvenile overlap syndrome with features of myositis and systemic sclerosis. J Rheumatol 2016; 43 (09) 1768-1769
    CrossrefPubMedGoogle Scholar
  • 11 Popescu NA, Manea D, Capitanescu G, Cinteza E, Ionescu MD, Balgradean M. Respiratory failure in a rare case of juvenile dermatomyositis: systemic scleroderma overlap syndrome. Maedica (Buchar) 2020; 15 (03) 394-400
    PubMedGoogle Scholar